Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial.

MLA

Block, Geoffrey A., et al. “Fibroblast Growth Factor 23 as a Risk Factor for Cardiovascular Events and Mortality in Patients in the EVOLVE Trial.” Hemodialysis International. International Symposium on Home Hemodialysis, vol. 25, no. 1, Jan. 2021, pp. 78–85. EBSCOhost, https://doi.org/10.1111/hdi.12887.

APA

Block, G. A., Chertow, G. M., Cooper, K., Xing, S., Fouqueray, B., Halperin, M., & Danese, M. D. (2021). Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodialysis International. International Symposium on Home Hemodialysis, 25(1), 78–85. https://doi.org/10.1111/hdi.12887

Chicago

Block, Geoffrey A, Glenn M Chertow, Kerry Cooper, Shan Xing, Bruno Fouqueray, Marc Halperin, and Mark D Danese. 2021. “Fibroblast Growth Factor 23 as a Risk Factor for Cardiovascular Events and Mortality in Patients in the EVOLVE Trial.” Hemodialysis International. International Symposium on Home Hemodialysis 25 (1): 78–85. doi:10.1111/hdi.12887.